Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury
Open Access
- 14 May 2008
- journal article
- review article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 14 (2) , 143-152
Abstract
Cilostazol increases intracellular cyclic adenosine monophosphate (cyclic AMP) levels by inhibiting type III phosphodiesterase. It was approved by the Food and Drug Administration for the treatment of intermittent claudication. Its principal actions include inhibition of platelet aggregation, antithrombotic action in cerebral ischemia, and vasodilation, mediated by increased cyclic AMP levels. In a multicenter, randomized, placebo‐controlled, double‐blind clinical trial, cilostazol has been shown to protect patients from recurrent cerebral infarction. It has been recently suggested that cilastozol could be useful in the treatment of transient focal cerebral ischemic injury. Beneficial effects of cilostazol in cerebral ischemic infarction and edema formation has been confirmed in rats by the magnetic resonance imaging (MRI). The preventive effect was ascribed to cAMP‐dependent protein kinase (PKA)‐coupled maxi‐K channel activation with additional antioxidant and poly(adenosine diphosphate [ADP]‐ribose) polymerase inhibitory actions. Most recently, cilostazol has been shown to prevent vacuolation and rarefaction in the white matter of the rats subjected to chronic cerebral hypoperfusion in association with suppression of astrocyte and microglial activation. Taken together, recent experimental studies with cilostazol showed promising results in cerebral ischemia and chronic cerebral hypoperfusion.Keywords
This publication has 79 references indexed in Scilit:
- Cilostazol Protects Against Brain White Matter Damage and Cognitive Impairment in a Rat Model of Chronic Cerebral HypoperfusionStroke, 2006
- Cilostazol Attenuates Gray and White Matter Damage in a Rodent Model of Focal Cerebral IschemiaStroke, 2006
- Cilostazol Prevents Focal Cerebral Ischemic Injury by Enhancing Casein Kinase 2 Phosphorylation and Suppression of Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Cilostazol Enhances Casein Kinase 2 Phosphorylation and Suppresses Tumor Necrosis Factor-α-Induced Increased Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation and Apoptotic Cell Death in SK-N-SH CellsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- White Matter Changes in the Gerbil Brain Under Chronic Cerebral HypoperfusionStroke, 1998
- Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhdbitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivoLife Sciences, 1997
- Alterations in Glia and Axons in the Brains of Binswanger’s Disease PatientsStroke, 1997
- The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of ApoptosisScience, 1997
- Cerebral White Matter Is Highly Vulnerable to IschemiaStroke, 1996
- Early changes in blood brain barrier permeability to small molecules after transient cerebral ischemia.Stroke, 1984